Activity and Content of Factor VIII (FVIII) in Human Plasma: The Assessment of a Novel Immunoassay
| Status: | Completed |
|---|---|
| Conditions: | Anemia, Hematology |
| Therapuetic Areas: | Hematology |
| Healthy: | No |
| Age Range: | 18 - Any |
| Updated: | 2/2/2017 |
| Start Date: | September 2006 |
| End Date: | February 2009 |
Pharmacokinetic (PK) Analysis of a Novel Immunoassay in Hemophilia A
A novel immuno-assay is being evaluated for the measurement of Factor VIII. Current
procedure measures a rate assay which is subject to much artefact. The hypothesis is that
the new assay will give a reading of absolute quantities of FVIII which will provide a more
suitable indicator of FVIII content for clotting factor manufacturers, physicians and
patients.
procedure measures a rate assay which is subject to much artefact. The hypothesis is that
the new assay will give a reading of absolute quantities of FVIII which will provide a more
suitable indicator of FVIII content for clotting factor manufacturers, physicians and
patients.
Remnant samples collected in a clinical laboratory are assayed with the new procedure and
compared with the standard functional activated partial thromboplastin time (APTT) assay. A
PK study in seven study subjects with hemophilia A is being carried out using five different
commercially licensed factor VIII concentrates and the blood samples drawn for the PK
analysis are being measured for FVIII with the novel assay and compared with the standard
APTT assay. The concentrates used in the PK studies are also being applied to the two assay
systems to determine each product's specific activity.
compared with the standard functional activated partial thromboplastin time (APTT) assay. A
PK study in seven study subjects with hemophilia A is being carried out using five different
commercially licensed factor VIII concentrates and the blood samples drawn for the PK
analysis are being measured for FVIII with the novel assay and compared with the standard
APTT assay. The concentrates used in the PK studies are also being applied to the two assay
systems to determine each product's specific activity.
Inclusion Criteria:
- adults with hemophilia A
- factor VIII less that 2%
- informed consent signed
- absence of an inhibitor
Exclusion Criteria:
- history of a high responding inhibitor anemia
We found this trial at
1
site
Click here to add this to my saved trials
